Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Bacterial vaccines save lives and constitute a major tool to address the challenge of anti-microbial resistance, though, despite their success, there is a relative paucity of such vaccines. Historically there has not been a network that focuses on bacterial vaccines, to promote sharing of approaches and best practices, and provide advocacy. BactiVac, the Bacterial Vaccines Network, was established in August 2017 to address this gap. Its mission is to advance vaccine development against global bacterial infections in humans and animals, to reduce disease, death, and antimicrobial resistance, and thereby enhance economic development. BactiVac brings together academia, industry, policymakers and funders from high-income countries (HICs) and low- and middle-income countries (LMICs), in a network of 2060 members from 92 countries, including 51 % from LMICs and 15 % from industry. BactiVac supports vaccine development through Catalyst Project Awards and Catalyst Training Awards. This funding targets bottlenecks and capacity-building in vaccinology, particularly among LMIC early-career researchers. Annual Network Meetings facilitate exchange of information and ideas, and new collaborations. We provide advocacy for bacterial vaccines nationally and internationally and, by partnering with aligned networks, function as a network within a network of networks. Therefore, through providing financial support and facilitating collaboration, BactiVac supports and enhances the bacterial vaccinology community to help reduce the devastating burden of disease caused by bacterial infections.

Original publication

DOI

10.1016/j.vaccine.2025.127210

Type

Journal article

Journal

Vaccine

Publication Date

05/2025

Volume

57

Addresses

Department of Immunology and Immunotherapy, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford OX3 7DQ, UK. Electronic address: calman.maclennan@ndm.ox.ac.uk.

Keywords

BactiVac Network Group of Authors